Developments in the treatment of severe influenza: Lessons from the pandemic of 2009 and new prospects for therapy

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 560-565

  Zambon, Maria ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antiviral; Influenza; Pandemic; Severe illness

Indexed keywords

ADAMANTANE; ANTIVIRUS AGENT; FAVIPIRAVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RECOMBINANT PROTEIN; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; SIALIDASE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; PANDEMIC INFLUENZA; PROTEIN ENGINEERING; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIRD; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; PANDEMIC; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIVIRAL AGENTS; BIRDS; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; POPULATION SURVEILLANCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ZANAMIVIR;

EID: 84927800376     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000113     Document Type: Review

References (32)

1. Hardelid P, Pebody R, Andrews N. Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010. Influenza Other Respir Viruses 2013; 7:35-45.
2. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-1436.
3. To KK, Chan JF, Yuen KY. Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Curr Opin Pulmon Med 2014; 20:225-232.
4. Wong KK, Gambhir M, Finelli L, et al. Transmissibility of variant influenza from swine to humans: a modeling approach. Clin Infect Dis 2013; 57 (Suppl 1):S16-22.
5. Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses 2013; 7 (Suppl s3):60-66.
6. Miller PE, Rambachan A, Hubbard RJ, et al. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study. PLoS One 2012; 7:e43491.
7. Sugaya N, Shinjoh M, Mitamura K, et al. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect 2011; 63:288-294.
8. World Health Organisation. Global Alert and Response (GAR): Pandemic (H1N1) 2009-update 90. Geneva; 2010; Available from: http://www.who.int/csr/don/2010-03-05/en/. [Accessed 19 August 2014]
9. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013; 57:1511-1519.
10. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother 2011; 17:595-601.
11. Loder E, Tovey D, Godlee F. The Tamiflu trials (editorial). BMJ 2014; 348:g2630.
12. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4:CD008965.
13. House of Commons Committee of Public Accounts. Access to clinical trial information and the stockpiling of Tamiflu, HC 29. London: The Stationery Office Limited; 2014.
14. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
15. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359-1366.
16. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
17. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-2279.
18. Pebody RG, Harris R, Kafatos G, et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) United Kingdom. Emerg Infect Dis 2011; 17:990-999.
19. Samson M, Pizzorno A, Abed Y, et al. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98:174-185.
20. Yates P, Mehta N, Hasan S, et al. Identification of resistance mutations as minority species in clinical specimens from hospitalised adults with influenza and treated with intravenous zanamivir. Proceedings of the third isirv-antiviral group conference; 4-6 June 2014; Tokyo; isirv Antiviral Group; c2014, p. 61.
21. Barzon L, Lavezzo E, Militello V, et al. Applications of next-generation sequencing technologies to diagnostic virology. Int J Mol Sci 2011; 12:7861-7884.
22. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:1-2.
23. Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors. Antiviral Res 2014; 110C:31-41.
24. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-454.
25. Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 2014; 16:141-144.
26. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009; 4:e7788.
27. Beigel JH, Luke TC. A study in scarlet-convalescent plasma for severe influenza. Crit Care Med 2012; 40:1027-1028.
28. Mair-Jenkins J, Saavedra-Campos M, Baillie K, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014. [Epub ahead of print]
29. Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses 2013; 7 (Suppl 3):52-59.
30. Trevejo J, Deng R, Burgess T, et al. Safety and efficacy of MHAA4549A, a novel monoclonal antibody for treatment of severe influenza A. Proceedings of the third isirv-antiviral group conference; 4-6 June 2014; Tokyo. isirv Antiviral Group. c2014. p. 38.
31. Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-850.
32. Friesen RH, Lee PS, Stoop EJ, et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 2014; 111:445-450.